According to a press release from Sloan Kettering, the new data suggests a baseline PSA could determine who should and should not continue to be screened for prostate cancer.
"We were hoping to find a novel marker," the press release quotes lead researchers Andrew Vickers andd Hans Lilja. "What we found instead was a new way of using an old test."
According to the study, 126 men were diagnosed with prostate cancer, and of those, 90 percent of deaths occurred in men in the top 25 percent of PSA levels at age 60. The researchers concluded that men with a PSA level above 2 ng/ml at age 60 should be considered at increased risk of aggressive prostate cancer and should continue to be screened regularly.
The study has been published in the “British Medical Journal”.